New drug targets 'Undruggable' cancer mutation in first human trial
NCT ID NCT07134998
Summary
This is the first study in people to test a new drug called HRS-6093, which is designed to target a specific genetic change (KRAS G12D mutation) found in some advanced solid tumors. The main goal is to find a safe dose and understand how the drug moves through the body in about 153 adults whose cancer has progressed after standard treatments. Researchers will also look for early signs that the drug might help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED KRAS G12D MUTANT SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Jiao Tong University School of Medicine
RECRUITINGShanghai, Shanghai Municipality, 200025, China
Contact
-
West China Hospital of Sichuan University
RECRUITINGChengdu, Sichuan, 610041, China
Contact
Conditions
Explore the condition pages connected to this study.